Section
A phase 1 trial demonstrates the safety and promising efficacy of expanded minor histocompatibility antigen-specific donor regulatory T cells as a novel prophylactic approach to reduce graft-versus-host disease and improve survival post-all
This retrospective nationwide study from Italy evaluates real-life first-line treatments for primary mediastinal B-cell lymphoma, highlighting treatment patterns, clinical outcomes, and challenges in managing this rare lymphoma subtype.
This study analyzes treatment patterns, outcomes, and prognostic factors in 344 patients with transformed follicular lymphoma in the rituximab era, revealing poor event-free survival but moderate overall survival and high relapse rates, gui
This phase 1 trial demonstrates that expanded minor histocompatibility antigen-specific donor regulatory T cells, combined with sirolimus prophylaxis, are safe and show promise in preventing acute and chronic GVHD post-allogeneic HCT with d
This article explores the pivotal role of Galectin-1 in enhancing monocyte-mediated inflammation in myeloproliferative neoplasms (MPNs) and highlights its potential as a novel therapeutic target through the TLR4-NF-κB signaling axis.
This article explores the discovery of NSD2-ligand-directed degrader (NSD2-LDD), a promising targeted therapy that degrades oncogenic NSD2 in t(4;14) multiple myeloma, reversing malignant epigenomic programs and improving disease outcomes i
This study evaluates the safety and clinical outcomes of immune checkpoint inhibitor rechallenge in classical Hodgkin lymphoma patients following immune-related adverse events, demonstrating feasibility and preserved efficacy in selected ca
This article highlights the discovery that TYK2 kinase is a selective therapeutic target in CALR-mutant myeloproliferative neoplasms, with combined TYK2 and JAK2 inhibition offering enhanced efficacy over JAK2 inhibition alone.
This review elucidates fibrocytes’ critical role in JAK2V617F-mutated myelofibrosis pathogenesis and evaluates pitavastatin’s promising therapeutic effects in reversing marrow fibrosis and anemia, integrating mechanistic insights and
Recent advances in identifying leukemia-restricted antigens enable subtype-specific immunotherapies in AML that selectively target malignant cells while sparing normal hematopoiesis, offering a promising new paradigm for precision treatment
Aberrant MERTK expression activates BCR signaling via CD79a in CLL, offering a novel therapeutic target. Inhibiting MERTK with UNC-2025 shows potential against ibrutinib-resistant relapse, especially combined with venetoclax.
Final phase 3 trial analysis confirms recombinant ADAMTS13 (rADAMTS13) provides effective prophylaxis with fewer acute and subacute TTP events and better safety than plasma-based therapy in congenital TTP patients.
This article elucidates how the TCA cycle enzyme IDH3 critically regulates metabolic fitness in AML stem cells, influencing venetoclax resistance and offering a novel target to improve therapeutic outcomes.
A comprehensive single-cell RNA sequencing study of large B cell lymphomas reveals five malignant B cell archetypes, with one subtype predictive of poor treatment response and survival, paving the way for precision therapy in LBCL.
Measurable residual disease (MRD) testing offers critical insights to tailor allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia, optimizing patient selection, conditioning intensity, and relapse surveillance
Soluble BCMA levels in newly diagnosed multiple myeloma patients reveal distinct tumor phenotypes and predict prognosis more strongly than tumor volume, enabling improved risk stratification and clinical decision-making.
This study reveals that lifelong genetic differences in LDL cholesterol levels do not significantly affect the risk of venous thromboembolism (VTE), suggesting LDL-C may not be a major causal factor in VTE development.
This study elucidates the incidence and characteristics of respiratory viral infections (RVIs) within 100 days following hematopoietic cell transplant and CAR T-cell therapy, highlighting SARS-CoV-2 as the predominant pathogen and identifyi
The addition of tyrosine kinase inhibitors to intensive chemotherapy markedly improves remission rates and overall survival in patients with de novo BCR::ABL1+ acute myeloid leukemia, suggesting a new standard of care approach.
This article explores the pivotal role of IGF2BP2, an N6-methyladenosine reader, in driving tumor growth and immune evasion in peripheral T-cell lymphoma, highlighting its potential as a dual-action therapeutic target.
